Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter

Region Västerbotten

Status: Completed

Conditions: Botulinum Toxins, Type A; Bite Force

Treatments: Drug: Botulinum toxin type A

Study type: Interventional

Funder types: Other

Identifiers

NCT05309564

BTX-Thailand

Details and patient eligibility

About

This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units).

Full description

This study aimed to evaluate the duration of a reduced maximal voluntary bite force (MVBF) after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units). A control group did not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the incisors and first molars. The intervention group was comprised of individuals seeking aesthetic treatment for masseter reduction (n = 20), and the control group (n = 12) comprised of volunteers.

Enrollment: 32 patients

Sex: Female

Ages: 18 to 120 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Healthy subjects seeking aesthetical treatment to reduce masseter muscle volume.

Exclusion criteria

Conditions or drugs affecting the central nervous system.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

32 participants in 2 patient groups

Intervention

Experimental group

Description:

Intervention with single botulinum neurotoxin injection into masseter.

Treatment:

Drug: Botulinum toxin type A

Control

No Intervention group

Description:

No intervention